Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Baselga

Showing results (31-40 of 126) with videos related to

Pageof 13
Sort By:
Drug Discovery Today|September 1, 2015
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trialsDavid M Hyman, David B Solit, Maria E Arcila, et al.
Journal of Geriatric Oncology|January 30, 2014
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancerLinda T Vahdat, Eduard Vrdoljak, Henry Gómez, et al.
Breast Cancer Research and Treatment|April 13, 2013
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancerShanu Modi, Cristina Saura, Charles Henderson, et al.
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Investigational New Drugs|September 8, 2010
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumorsEduardo Vilar, Viktor Grünwald, Patrick Schöffski, et al.
Cancer Cell|February 13, 2007
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B geneAlejandra Bruna, Rachel S Darken, Federico Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancerGiulia Bianchi, John Albanell, Wolfgang Eiermann, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine TumorsAdriana Soler, Ana M Figueiredo, Pau Castel, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trialJames A Bonner, Jordi Giralt, Paul M Harari, et al.
Pageof 13

Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Drug Discovery Today|September 1, 2015
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trialsDavid M Hyman, David B Solit, Maria E Arcila, et al.
Journal of Geriatric Oncology|January 30, 2014
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancerLinda T Vahdat, Eduard Vrdoljak, Henry Gómez, et al.
Breast Cancer Research and Treatment|April 13, 2013
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancerShanu Modi, Cristina Saura, Charles Henderson, et al.
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Investigational New Drugs|September 8, 2010
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumorsEduardo Vilar, Viktor Grünwald, Patrick Schöffski, et al.
Cancer Cell|February 13, 2007
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B geneAlejandra Bruna, Rachel S Darken, Federico Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancerGiulia Bianchi, John Albanell, Wolfgang Eiermann, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine TumorsAdriana Soler, Ana M Figueiredo, Pau Castel, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trialJames A Bonner, Jordi Giralt, Paul M Harari, et al.
Pageof 13